Preliminary NICE ‘no’ for Merck’s Bavencio
The cost regulator has rejecting funding the drug as maintenance treatment of advanced/metastatic urothelial cancer
Read More
Tag: avelumab
UK bladder cancer patients get early access to Bavencio
UK MHRA has issued positive scientific opinion enabling the drug’s inclusion on the Early Access to Medicines Scheme
Read More
NICE green light for immunotherapy Bavencio
Merck and Pfizer’s drug will now be available on the NHS in combination with axitinib as a first-line treatment for kidney cancer
Read More
NICE backs Bavencio combo for kidney cancer
The combination of an immunotherapy with a targeted antiangiogenic therapy offers patients a novel treatment option
Read More
US approves Bavencio for bladder cancer
In a clinical trial, Bavencio maintenance treatment extended median overall survival by 50% over standard of care
Read More
EMA to consider expanding use of Merck/Pfizer’s Bavencio
The regulator will assess its safety and efficacy as a treatment for bladder cancer
Read More
MHRA gives Bavencio, Inlyta combo Early Access to Medicines status
The opinion is for the indication of RCC, the most common kind of kidney cancer found in adults.
Read More
FDA approval for Bavencio combo in advanced RCC
The decision was based on positive results from the Phase III JAVELIN Renal 101 study.
Read More
Merck, Pfizer pull the plug on ovarian cancer trial
Merck and Pfizer are pulling the plug on a late-stage trial assessing the potential of their PD-L1 antibody avelumab in the front-line maintenance setting for ovarian cancer.
Read More
Merck, Pfizer’s Bavencio misses ovarian cancer trial endpoints
A late-stage study testing Merck KGaA and Pfizer’s PD-L1 antibody Bavencio has failed to meet its primary endpoints in patients with certain forms of ovarian cancer.
Read More
Five therapies endorsed for use on NHS Scotland
A new treatment option for the very rare condition infantile onset 5q spinal muscular atrophy (type I SMA) is among five medicines that have been endorsed by Scottish cost regulators for use on the NHS.
Read More
Final guidance from NICE on Merck, Pfizer’s Bavencio
The National Institute for Health and Care Excellence has now published final guidelines endorsing Merck and Pfizer’s Bavencio as an option for patients with Merkel cell carcinoma (MCC).
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
